Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Commentary|Articles|May 7, 2026
FAQ: Teplizumab and Its Expanded FDA Indication
Author(s)Gillian McGovern, Editor
Fact checked by: Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, Ron Panarotti
FDA expands teplizumab to age 1 year for stage 2 type 1 diabetes—pharmacists must learn dosing, infusion logistics, and safety monitoring.
Advertisement
Advertisement
This FAQ was fact-checked by Jennifer Goldman, PharmD, CDCES, BC‑ADM, FCCP.
Related to this article
Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Advertisement
Advertisement